Travere Therapeutics, INC Form 4 insider transactions

Elizabeth E. Reed, SVP, GC & Corporate Secretary of Travere Therapeutics, exercises performance-based restricted stock units (PSUs) and sells shares to cover tax obligations after a key regulatory milestone for FILSPARI.

Sandra Calvin, SVP and Chief Accounting Officer of Travere Therapeutics, exercised stock options and sold shares on February 11, 2025, according to a recent SEC Form 4 filing.

Chief Commercial Officer Peter Heerma exercised performance-based restricted stock units (PSUs) and sold shares of Travere Therapeutics following the confirmation of a path forward for traditional approval of FILSPARI in FSGS.

Travere Therapeutics CEO Eric Dube sold 11,375 shares of common stock at $24.04 per share on February 11, 2025, under a pre-arranged 10b5-1 trading plan.

Jula Inrig, Chief Medical Officer of Travere Therapeutics, sold shares to cover tax obligations following the vesting of performance-based restricted stock units (PSUs) due to the satisfaction of clinical/regulatory performance criteria.

Director Roy D. Baynes exercised stock options and sold 10,000 shares of Travere Therapeutics (TVTX) common stock at $22 per share on February 6, 2025.

Senior Vice President of R&D at Travere Therapeutics, William E. Rote, reports acquisition and disposal of company stock and stock options.

Elizabeth Reed, SVP, GC & Corporate Secretary of Travere Therapeutics, reports acquisition of restricted stock units and stock options, and the sale of common stock to cover tax obligations.

CEO Eric Dube reports acquisition and disposal of Travere Therapeutics stock, including sales to cover tax obligations.

Chief Medical Officer Jula Inrig acquired shares and sold a portion to cover tax obligations related to vested restricted stock units.

Chief Commercial Officer Peter Heerma of Travere Therapeutics reports acquisition of stock options and sale of shares to cover tax obligations.

Christopher Cline, CFO of Travere Therapeutics, reports acquisition of stock options and restricted stock units, as well as a sale of shares to cover tax obligations.

Sandra Calvin, SVP, Chief Accounting Officer of Travere Therapeutics, reports acquisition of 13,000 shares and sale of 3,348 shares to cover tax obligations.

A Travere Therapeutics executive, William E. Rote, sold 2,437 shares of common stock at $19.46 per share under a pre-arranged 10b5-1 trading plan.

Travere Therapeutics CEO, Eric M. Dube, sold 10,736 shares of common stock at $19.46 per share on January 22, 2025, under a pre-arranged 10b5-1 trading plan.

Elizabeth E. Reed, SVP, GC & Corporate Secretary of Travere Therapeutics, sold 2,437 shares of common stock at $19.46 per share under a pre-arranged 10b5-1 trading plan.

A Travere Therapeutics director, Roy D. Baynes, exercised stock options and sold shares on January 23, 2025, according to a recent SEC filing.

Peter Heerma, Chief Commercial Officer of Travere Therapeutics, sold 1,584 shares to cover tax obligations related to vested restricted stock units.

Travere Therapeutics' Chief Financial Officer, Christopher R. Cline, sold 865 shares of common stock to cover tax obligations related to vested restricted stock units.

A Travere Therapeutics executive sold 925 shares of common stock to cover tax obligations related to vested restricted stock units.

Travere Therapeutics' Chief Medical Officer, Jula Inrig, sold shares to cover tax obligations related to vested restricted stock units.

A Travere Therapeutics executive, Sandra Calvin, exercised stock options and sold shares on December 26, 2024, under a pre-arranged 10b5-1 trading plan.

A Travere Therapeutics executive, Sandra Calvin, exercised stock options and sold a portion of the acquired shares to cover tax obligations.

Director Gary Lyons exercised stock options and sold shares of Travere Therapeutics under a pre-arranged 10b5-1 trading plan.

Director Jeffrey A. Meckler exercised stock options and sold 40,000 shares of Travere Therapeutics (TVTX) at an average price of $14.0581 on September 30, 2024.

Jula Inrig, Chief Medical Officer of Travere Therapeutics, sold 684 shares of common stock at $12.98 per share on September 10, 2024, under a pre-arranged 10b5-1 trading plan.

William E. Rote, Senior Vice President of R&D at Travere Therapeutics, sold 4,387 shares of company stock after performance stock units vested following FDA approval of FILSPARI.

Elizabeth E. Reed, SVP, GC & Corporate Secretary of Travere Therapeutics, sold 4,387 shares of common stock after performance stock units vested following FDA approval of FILSPARI.

Travere Therapeutics CEO Eric M. Dube exercised performance restricted stock units (PSUs) and sold shares to cover tax obligations after the FDA granted full approval to FILSPARI for IgA Nephropathy.

Following the FDA's full approval of FILSPARI, Travere Therapeutics' Chief Medical Officer, Jula Inrig, reports acquisition of shares through vested performance stock units and subsequent sale to cover tax obligations.